Basic Study
Copyright ©The Author(s) 2016.
World J Clin Oncol. Oct 10, 2016; 7(5): 387-394
Published online Oct 10, 2016. doi: 10.5306/wjco.v7.i5.387
Table 4 Comparison of tumor-infiltrating-lymphocyte evaluated in pre- vs post-neoadjuvant-chemotherapy samples
Population of lymphocytesnPre-NAC Me ± IQRPost-NAC Me ± IQRP-value2P corrected value3
Percentage
H and E whole slide7340 ± 1520 ± 15< 0.001< 0.0021
H and E TMA1630 ± 17.515 ± 150.4321
Absolute counting
CD322244.5 ± 315.5255.5 ± 2670.8583
CD4714 ± 9432 ± 430.6721
CD821127 ± 193.5156 ± 90.50.7544
FOXP32118 ± 3112 ± 19.50.0917

  • Citation: Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol 2016; 7(5): 387-394
  • URL: https://www.wjgnet.com/2218-4333/full/v7/i5/387.htm
  • DOI: https://dx.doi.org/10.5306/wjco.v7.i5.387